Spots Global Cancer Trial Database for merkel cell carcinoma
Every month we try and update this database with for merkel cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | NCT03787602 | Merkel Cell Car... | KRT-232 Avelumab | 18 Years - | Kartos Therapeutics, Inc. | |
| Hypofractionated Radiation Therapy for Merkel Cell Carcinoma | NCT05100095 | Merkel Cell Car... | Radiation thera... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | NCT02819843 | Melanoma Merkel Cell Car... Other Solid Tum... | TALIMOGENE LAHE... Hypofractionate... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy | NCT03853317 | Merkel Cell Car... | Avelumab N-803 haNK™ | 18 Years - | ImmunityBio, Inc. | |
| The Impact of Total Body Skin Examination on Skin Cancer Detection | NCT00765193 | Melanoma Basal Cell Carc... Squamous Cell C... Merkel Cell Car... Skin Cancer | Inspection of c... | 18 Years - 95 Years | Medical University of Graz | |
| Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | NCT02036476 | Merkel Cell Car... Skin Cancer | Cabozantinib | 18 Years - | Dana-Farber Cancer Institute | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | NCT04106167 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small-cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | Allogeneic natu... | 18 Years - | Fate Therapeutics | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | NCT04590781 | Merkel Cell Car... Small Cell Lung... | XmAb18087 XmAb18087 ± Pem... | 18 Years - | Xencor, Inc. | |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | NCT03935893 | Gastric Cancer Colorectal Canc... Pancreatic Canc... Sarcoma Mesothelioma Neuroendocrine ... Squamous Cell C... Merkel Cell Car... Mismatch Repair... Microsatellite ... | Tumor Infiltrat... Fludarabine + C... | 18 Years - 75 Years | University of Pittsburgh | |
| Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma | NCT03988647 | Merkel Cell Car... | Pembrolizumab Radiation Thera... | 18 Years - | Stanford University | |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | NCT02831179 | Functional Panc... Malignant Somat... Merkel Cell Car... Metastatic Adre... Metastatic Carc... Multiple Endocr... Multiple Endocr... Multiple Endocr... Neuroendocrine ... Non-Functional ... Pancreatic Gluc... Pancreatic Insu... Recurrent Adren... Recurrent Adren... Recurrent Merke... Somatostatin-Pr... Stage III Adren... Stage III Thyro... Stage IIIA Merk... Stage IIIB Merk... Stage IV Adrena... Stage IV Merkel... Stage IVA Thyro... Stage IVB Thyro... Stage IVC Thyro... Thymic Carcinoi... VIP-Producing N... Well Differenti... Zollinger Ellis... | Capecitabine Temozolomide Veliparib Pharmacological... Laboratory Biom... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | NCT04260802 | Cancer Neoplasms Metastatic Canc... Triple Negative... Gastric Cancer Cervical Cancer Ovarian Cancer Hepatocellular ... Squamous Cell C... Urothelial Carc... Urothelial Neop... Non Small Cell ... Renal Cell Carc... Locally Advance... Locally Advance... Squamous Cell C... Sarcoma Merkel Cell Car... Bladder Cancer | OC-001 OC-001 in Combi... | 18 Years - | Ocellaris Pharma, Inc. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma | NCT01652547 | Metastatic Mela... | Pasireotide sub... Pasireotide lon... | 18 Years - | Novartis | |
| Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | NCT03798639 | Merkel Cell Car... Pathologic Stag... Pathologic Stag... | Ipilimumab Nivolumab Radiation Thera... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma | NCT04291885 | Merkel Cell Car... Merkel Cell Car... Merkel Cell Car... Merkel Cell Car... Neuroendocrine ... Carcinoma Neuro... | Avelumab Placebo | 18 Years - | Melanoma and Skin Cancer Trials Limited | |
| Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma | NCT06056895 | Unresectable Cl... Clinical Stage ... Merkel Cell Car... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Retifanlimab Tuparstobart Verzistobart | 18 Years - | University of Washington | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer | NCT01440816 | Merkel Cell Car... | Tavokinogene Te... OncoSec Medical... | 18 Years - | OncoSec Medical Incorporated | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy | NCT05358938 | Cutaneous Melan... Cutaneous Squam... Merkel Cell Car... | Exercise Checkpoint Bloc... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma | NCT05496036 | Merkel Cell Car... | Pembrolizumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| T-VEC in Non-melanoma Skin Cancer | NCT03458117 | Non-melanoma Sk... Basal Cell Carc... Squamous Cell C... Cutaneous Lymph... Merkel Cell Car... | Talimogene Lahe... | 18 Years - | University of Zurich | |
| EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | NCT06223659 | Cutaneous Melan... Merkel Cell Car... Skin Squamous C... | Eutectic Mixtur... Placebo Adminis... Questionnaire A... | 18 Years - 99 Years | Ohio State University Comprehensive Cancer Center | |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | NCT02978625 | Adenoid Cystic ... Adnexal Carcino... Anaplastic Larg... Anaplastic Larg... Apocrine Carcin... Cylindrocarcino... Digital Papilla... Endocrine Mucin... Extramammary Pa... Extraocular Cut... Hidradenocarcin... Keratoacanthoma Malignant Sweat... Merkel Cell Car... Microcystic Adn... NK-Cell Lymphom... Papillary Adeno... Porocarcinoma Primary Cutaneo... Recurrent Matur... Recurrent T-Cel... Refractory Anap... Refractory Matu... Refractory Merk... Refractory Myco... Refractory Prim... Refractory Skin... Refractory T-Ce... Sezary Syndrome Signet Ring Cel... Skin Basal Cell... Skin Basosquamo... Skin Squamous C... Spiradenocarcin... Squamoid Eccrin... Squamous Cell C... Sweat Gland Car... Trichilemmal Ca... Vulvar Squamous... | Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Nivolumab Positron Emissi... Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | NCT02643303 | Head and Neck S... Breast Cancer Sarcoma Merkel Cell Car... Cutaneous T-Cel... Melanoma Renal Cancer Bladder Cancer Prostate Cancer Testicular Canc... Solid Tumor | Durvalumab Tremelimumab Poly-ICLC | 18 Years - | Ludwig Institute for Cancer Research | |
| Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO | NCT05078047 | Lung Cancer Met... Renal Cell Carc... Head and Neck C... Bladder Cancer Triple Negative... Merkel Cell Car... Hepatocellular ... Melanoma | Reduced dose in... | 18 Years - | UNICANCER | |
| Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation | NCT02196961 | Merkel Cell Car... | Nivolumab | 18 Years - | University Hospital, Essen | |
| Merkel Positron Emission Tomography (PET) Protocol | NCT01013779 | Merkel Cell Car... | Carboplatin Etoposide Radiotherapy | 18 Years - | Trans Tasman Radiation Oncology Group | |
| SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines | NCT04705389 | Merkel Cell Car... | Samples | - | University Hospital, Tours | |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | NCT04106167 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small-cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | Allogeneic natu... | 18 Years - | Fate Therapeutics | |
| Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus | NCT02479698 | Acquired Immuno... BK Virus Infect... Human Immunodef... JC Virus Infect... Malignant Neopl... Merkel Cell Car... Merkel Cell Pol... Viral Encephali... | Allogeneic BK-s... Laboratory Biom... | - | M.D. Anderson Cancer Center | |
| A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma | NCT02035657 | Merkel Cell Car... | GLA-SE | 18 Years - 80 Years | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors | NCT00346385 | Ovarian Cancer Merkel Cell Car... SCLC | BB-10901 | 18 Years - | ImmunoGen, Inc. | |
| Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC) | NCT06086288 | Merkel Cell Car... | Pembrolizumab, ... | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Hypofractionated Radiation Therapy for Merkel Cell Carcinoma | NCT05100095 | Merkel Cell Car... | Radiation thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma | NCT04291885 | Merkel Cell Car... Merkel Cell Car... Merkel Cell Car... Merkel Cell Car... Neuroendocrine ... Carcinoma Neuro... | Avelumab Placebo | 18 Years - | Melanoma and Skin Cancer Trials Limited | |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | NCT05592626 | Advanced Solid ... Genital Neoplas... Urogenital Neop... Lung Neoplasm Neoplasms by Si... Papillomavirus ... Epstein-Barr Vi... Carcinoma Neoplasms Vulvar Neoplasm... Vulvar Diseases Abdominal Neopl... | STAR0602 | 18 Years - | Marengo Therapeutics, Inc. | |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | NCT02978625 | Adenoid Cystic ... Adnexal Carcino... Anaplastic Larg... Anaplastic Larg... Apocrine Carcin... Cylindrocarcino... Digital Papilla... Endocrine Mucin... Extramammary Pa... Extraocular Cut... Hidradenocarcin... Keratoacanthoma Malignant Sweat... Merkel Cell Car... Microcystic Adn... NK-Cell Lymphom... Papillary Adeno... Porocarcinoma Primary Cutaneo... Recurrent Matur... Recurrent T-Cel... Refractory Anap... Refractory Matu... Refractory Merk... Refractory Myco... Refractory Prim... Refractory Skin... Refractory T-Ce... Sezary Syndrome Signet Ring Cel... Skin Basal Cell... Skin Basosquamo... Skin Squamous C... Spiradenocarcin... Squamoid Eccrin... Squamous Cell C... Sweat Gland Car... Trichilemmal Ca... Vulvar Squamous... | Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Nivolumab Positron Emissi... Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | NCT03841110 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small Cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | FT500 Nivolumab Pembrolizumab Atezolizumab Cyclophosphamid... Fludarabine IL-2 | 18 Years - | Fate Therapeutics | |
| Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma | NCT06056895 | Unresectable Cl... Clinical Stage ... Merkel Cell Car... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Retifanlimab Tuparstobart Verzistobart | 18 Years - | University of Washington | |
| Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | NCT04590781 | Merkel Cell Car... Small Cell Lung... | XmAb18087 XmAb18087 ± Pem... | 18 Years - | Xencor, Inc. | |
| Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma | NCT05496036 | Merkel Cell Car... | Pembrolizumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Optical Biopsy of Human Skin in Conjunction With Laser Treatment | NCT00540566 | Malignant Melan... Merkel Cell Car... Basal Cell Carc... Squamous Cell C... Atypical Nevi Congenital Nevi Seborrheic Kera... Paget's Disease Dermatofibroma Kaposi's Sarcom... Port Wine Stain Hemangioma Tattoos Scleroderma Burns | Optical Biopsy ... | 18 Years - 75 Years | University of California, Irvine | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns | NCT06039033 | Merkel Cell Car... | 18 Years - | Power Life Sciences Inc. | ||
| T-VEC in Non-melanoma Skin Cancer | NCT03458117 | Non-melanoma Sk... Basal Cell Carc... Squamous Cell C... Cutaneous Lymph... Merkel Cell Car... | Talimogene Lahe... | 18 Years - | University of Zurich | |
| Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors | NCT04234113 | Thyroid Renal Cell Carc... Non Small Cell ... Small-cell Lung... Bladder Cancer Melanoma Merkel Cell Car... Skin Squamous C... Microsatellite ... Triple Negative... Mesothelioma Thymic Cancer Cervical Cancer Biliary Tract C... Hepatocellular ... Ovarian Cancer Gastric Cancer Head and Neck S... Anal Cancer | SO-C101 pembrolizumab | 18 Years - | Sotio Biotech Inc. | |
| Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) | NCT03783078 | Merkel Cell Car... | Pembrolizumab (... | 12 Years - | Merck Sharp & Dohme LLC | |
| Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC | NCT05253144 | Merkel Cell Car... | Radiotherapy Surgery | 18 Years - | University of Birmingham | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer | NCT01526486 | Melanoma Merkel Cell Car... Squamous Cell C... Penile Carcinom... Urethral Carcin... Extramammary Pa... Scrotal Carcino... Anal Cancer Vulvar Cancer Skin Cancer Lymphadenopathy | Videoscopic pro... Open, tradition... | 18 Years - 80 Years | Emory University | |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | NCT04725331 | Metastatic Canc... Soft Tissue Sar... Merkel Cell Car... Melanoma Triple Negative... Non Small Cell ... | BT-001 Pembrolizumab [... | 18 Years - | Transgene | |
| French National Database of Rare Dermatological Cancers | NCT03210935 | Adnexal Tumor o... Merkel Cell Car... Advanced Basal ... | - | University Hospital, Lille | ||
| LITT and Pembrolizumab in Recurrent Brain Metastasis | NCT04187872 | Melanoma Non-small Cell ... Renal Cell Carc... Small-cell Lung... Head and Neck S... Classical Hodgk... Primary Mediast... Urothelial Carc... Microsatellite ... Gastric Cancer Esophageal Canc... Cervical Cancer Hepatocellular ... Merkel Cell Car... Brain Metastase... | LITT + Pembroli... | 18 Years - 100 Years | University of Florida | |
| Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma | NCT04975152 | Merkel Cell Car... Cutaneous Squam... | Cemiplimab-Rwlc | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | NCT02819843 | Melanoma Merkel Cell Car... Other Solid Tum... | TALIMOGENE LAHE... Hypofractionate... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes | NCT03370861 | Autoimmunity Melanoma Merkel Cell Car... Squamous Cell C... Basal Cell Carc... Skin Cancer | Immunotherapy | 18 Years - | Washington University School of Medicine | |
| In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | NCT04616248 | Anatomic Stage ... Metastatic Brea... Prognostic Stag... Unresectable Br... Metastatic Mela... Unresectable Me... Cutaneous Squam... Merkel Cell Car... Soft Tissue Sar... Bone Sarcoma Sarcoma,Soft Ti... Sarcoma of Bone | Anti-CD40 Agoni... Poly ICLC Radiation Thera... Recombinant Flt... | 18 Years - | University of Southern California | |
| High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | NCT03901573 | Melanoma Merkel Cell Car... Cutaneous Squam... | NT-I7 atezolizumab | 18 Years - | NeoImmuneTech | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy | NCT05358938 | Cutaneous Melan... Cutaneous Squam... Merkel Cell Car... | Exercise Checkpoint Bloc... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors | NCT03684785 | Advanced or Met... Advanced or Met... Advanced or Met... Advanced or Met... Advanced or Met... | Cavrotolimod Pembrolizumab Cemiplimab Cavrotolimod | 18 Years - | Exicure, Inc. | |
| Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer | NCT05583708 | Merkel Cell Car... | Pembrolizumab Lutetium Lu 177... | 18 Years - | Weill Medical College of Cornell University | |
| Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC | NCT05253144 | Merkel Cell Car... | Radiotherapy Surgery | 18 Years - | University of Birmingham | |
| Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns | NCT06039033 | Merkel Cell Car... | 18 Years - | Power Life Sciences Inc. | ||
| Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery | NCT05594290 | Merkel Cell Car... | Retifanlimab Cisplatin Etoposide | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | NCT04590781 | Merkel Cell Car... Small Cell Lung... | XmAb18087 XmAb18087 ± Pem... | 18 Years - | Xencor, Inc. | |
| French National Database of Rare Dermatological Cancers | NCT03210935 | Adnexal Tumor o... Merkel Cell Car... Advanced Basal ... | - | University Hospital, Lille | ||
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | NCT04106167 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small-cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | Allogeneic natu... | 18 Years - | Fate Therapeutics | |
| A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | NCT03241173 | Advanced Malign... | INCAGN01949 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer | NCT05583708 | Merkel Cell Car... | Pembrolizumab Lutetium Lu 177... | 18 Years - | Weill Medical College of Cornell University | |
| Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma | NCT04792073 | Merkel Cell Car... | Avelumab Comprehensive A... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Studies of Dermatologic Diseases Biospecimen Acquisition Protocol | NCT02471352 | Dermatologic Co... Healthy Volunte... Normal Voluntee... Carcinoma, Merk... | 1 Day - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | NCT02831179 | Functional Panc... Malignant Somat... Merkel Cell Car... Metastatic Adre... Metastatic Carc... Multiple Endocr... Multiple Endocr... Multiple Endocr... Neuroendocrine ... Non-Functional ... Pancreatic Gluc... Pancreatic Insu... Recurrent Adren... Recurrent Adren... Recurrent Merke... Somatostatin-Pr... Stage III Adren... Stage III Thyro... Stage IIIA Merk... Stage IIIB Merk... Stage IV Adrena... Stage IV Merkel... Stage IVA Thyro... Stage IVB Thyro... Stage IVC Thyro... Thymic Carcinoi... VIP-Producing N... Well Differenti... Zollinger Ellis... | Capecitabine Temozolomide Veliparib Pharmacological... Laboratory Biom... | 18 Years - | Vanderbilt-Ingram Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
